 Connection
Neil Aggarwal to Hospitalization
This is a "connection" page, showing publications Neil Aggarwal has written about Hospitalization.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.909 |
|
|
|
-
Aggarwal NR, Nordwall J, Braun DL, Chung L, Coslet J, Der T, Eriobu N, Ginde AA, Hayanga AJ, Highbarger H, Holodniy M, Horcajada JP, Jain MK, Kim K, Laverdure S, Lundgren J, Natarajan V, Nguyen HH, Pett SL, Phillips A, Poulakou G, Price DA, Robinson P, Rogers AJ, Sandkovsky U, Shaw-Saliba K, Sturek JM, Trautner BW, Waters M, Reilly C. Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19. Clin Infect Dis. 2024 06 14; 78(6):1490-1503.
Score: 0.398
-
Agarwal T, Beaty LE, Carlson NE, Bennett TD, Fish LE, Mayer DA, Molina KC, Peers JL, Webb BJ, Xiao M, Ginde AA, Aggarwal NR. Association of remdesivir treatment with long-term mortality after COVID-19 hospitalization. BMC Infect Dis. 2025 Oct 28; 25(1):1418.
Score: 0.109
-
Molina KC, Webb BJ, Kennerley V, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Peers JL, Russell S, Wynia MK, Aggarwal NR, Ginde AA. Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5. BMC Infect Dis. 2024 Aug 08; 24(1):802.
Score: 0.100
-
Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Davis CB, Kwan BM, Mayer DA, Ong TC, Russell S, Steele J, Wogu AF, Wynia MK, Zane RD, Ginde AA. Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients. J Infect Dis. 2022 12 13; 226(12):2129-2136.
Score: 0.090
-
Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Molina KC, Peers JL, Russell S, Wynia MK, Ginde AA. Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase. Int J Infect Dis. 2023 Mar; 128:310-317.
Score: 0.088
-
Baker JV, Siegel LK, Losso MH, Vasudeva S, Nordwall JA, Harper K, Grund B, Havens JP, Fletcher CV, Fishchuk R, Kobrynska O, Abutidze A, Metchurtchlishvili R, Ginde AA, Aggarwal NR, Poulakou G, Mourad A, Gibbs KW, Saito S, Chayakulkeeree M, Mootsikapun P, Honda H, Mateu L, Gyrina O, Garcia A, Lee DG, Casey JD, Jain MK, Bengtson CD, Hite RD, Hiranburana N, Matthay MA, Arizmendez N, Nguyen HH, Drelick A, Mena Lora AJ, Parnia S, Trautner BW, Portsmouth SD, Shimizu R, Uehara T, Paredes R, Goodman AL, Vock DM, Gelijns AC, Weintrob AC, Bajema KL, Pett SL, Lundgren J, Schechner AJ, Higgs ES, Lane HC, Matthews GV, Self WH, Reilly C. Ensitrelvir for the Treatment of Hospitalized Adults With COVID-19: An International Phase 3 Randomized Placebo-controlled Trial. Clin Infect Dis. 2026 Jul 23; 83(1):59-69.
Score: 0.029
-
Wilson JG, Grandits GA, Grund B, Mistry SS, Leroux C, Ringor A, Aggarwal NR, Murray DD, Barkauskas CE, Brown SM, Higgs E, Shaw-Saliba K, Rupert A, Kan VL, Beitler JR, Awan O, Sturgill JL, Dawood H, Kalil AC, Kalomenidis I, Duggal A, Sasson SC, Ho MQ, Nguyen HH, Lundgren JD, Ginde AA, Self WH, Lane HC, Matthay MA, Rogers AJ. Prognostic Value of Lung Injury Biomarkers in Patients Hospitalized With COVID-19 Without Respiratory Failure at Admission. Crit Care Med. 2026 Aug 01; 54(8):1979-1989.
Score: 0.028
-
Xiao M, Molina KC, Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Fish LE, Hamer MK, Kwan BM, Mayer DA, Peers JL, Wynia MK, Ginde AA. A Machine Learning Method for Allocating Scarce COVID-19 Monoclonal Antibodies. JAMA Health Forum. 2024 09 06; 5(9):e242884.
Score: 0.025
-
Douin DJ, Wogu AF, Beaty LE, Carlson NE, Bennett TD, Aggarwal NR, Mayer DA, Ong TC, Russell S, Steele J, Peers JL, Molina KC, Wynia MK, Ginde AA. Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients. BMC Infect Dis. 2022 Nov 07; 22(1):818.
Score: 0.022
-
Casey JD, Johnson NJ, Semler MW, Collins SP, Aggarwal NR, Brower RG, Chang SY, Eppensteiner J, Filbin M, Gibbs KW, Ginde AA, Gong MN, Harrell F, Hayden DL, Hough CL, Khan A, Leither LM, Moss M, Oldmixon CF, Park PK, Reineck LA, Ringwood NJ, Robinson BRH, Schoenfeld DA, Shapiro NI, Steingrub JS, Torr DK, Weissman A, Lindsell CJ, Rice TW, Thompson BT, Brown SM, Self WH. Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19. Ann Am Thorac Soc. 2020 09; 17(9):1144-1153.
Score: 0.019
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|